Clearmind Medicine shares surge 31.55% after-hours after DSMB approves trial continuation and Israel site activates.

Clearmind Medicine Inc. surged 31.55% in after-hours trading following the announcement of three pivotal milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic oral therapy targeting Alcohol Use Disorder (AUD). The company reported positive top-line safety and efficacy results from the first cohort of six participants across elite U.S. institutions, including Johns Hopkins and Yale. An independent Data and Safety Monitoring Board (DSMB) then unanimously approved the trial’s continuation after an unblinded safety review. Additionally, enrollment commenced at Tel Aviv Sourasky Medical Center in Israel, accelerating multinational recruitment. These developments underscore progress in validating CMND-100’s potential to address a $249 billion annual market with limited effective treatments, bolstering investor confidence in the biotech’s clinical and commercial prospects.